AR and posterior cortical atrophy: Critically, heterogeneous AR enhancer usage in subsets of patients distinguishes patients on the outcome, indicating that epigenetic heterogeneity may be relevant in disease progression and could provide important opportunities to the field in advancing and personalizing PCa screening or treatment.